{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["19(9-10)"],"submitter":["Le DCP"],"pubmed_abstract":["<b>Background:</b> Heart failure (HF) causes over 266,400 deaths annually. Despite treatment advancements, HF mortality remains high. Induced pluripotent stem cells (iPSCs) offer promising new options. This review assesses iPSC-based treatments for HF.<b>Method:</b> the review included studies from PubMed, ScienceDirect and Web of Science.<b>Results:</b> Analysis of 25 studies with 553 animals showed a baseline ejection fraction (EF) of 39.2 ± 8.9%. iPSC treatment significantly improved EF (MD = 8.6, <i>p</i> < 0.001) and fractional shortening (MD = 6.38, <i>p</i> < 0.001), and reduced ventricular remodeling without increasing arrhythmia risk.<b>Conclusion:</b> iPSC-based therapy improves heart function and reduces ventricular volumes in HF animal models, aligning with promising early clin"],"journal":["Regenerative medicine"],"pagination":["497-509"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11487948"],"repository":["biostudies-literature"],"pubmed_title":["Induced pluripotent stem cell therapies in heart failure treatment: a meta-analysis and systematic review."],"pmcid":["PMC11487948"],"pubmed_authors":["Vo QD","Le DCP","Bui HT","Vu YTH"],"additional_accession":[]},"is_claimable":false,"name":"Induced pluripotent stem cell therapies in heart failure treatment: a meta-analysis and systematic review.","description":"<b>Background:</b> Heart failure (HF) causes over 266,400 deaths annually. Despite treatment advancements, HF mortality remains high. Induced pluripotent stem cells (iPSCs) offer promising new options. This review assesses iPSC-based treatments for HF.<b>Method:</b> the review included studies from PubMed, ScienceDirect and Web of Science.<b>Results:</b> Analysis of 25 studies with 553 animals showed a baseline ejection fraction (EF) of 39.2 ± 8.9%. iPSC treatment significantly improved EF (MD = 8.6, <i>p</i> < 0.001) and fractional shortening (MD = 6.38, <i>p</i> < 0.001), and reduced ventricular remodeling without increasing arrhythmia risk.<b>Conclusion:</b> iPSC-based therapy improves heart function and reduces ventricular volumes in HF animal models, aligning with promising early clin","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep-Oct","modification":"2026-06-03T02:28:17.644Z","creation":"2026-04-23T03:09:54.87Z"},"accession":"S-EPMC11487948","cross_references":{"pubmed":["39263954"],"doi":["10.1080/17460751.2024.2393558"]}}